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HIGHLIGHTS 
 Only measurement of maximal left atrial volume index is included in current 
echocardiographic guidelines 
 Left atrial emptying fraction is superior to maximal left atrial volume index  
 Left atrial emptying fraction predicts all-cause mortality in HFrEF  
 
 
 
ABSTRACT 
Background: The prognostic value of LA functional measures in heart failure patients with 
reduced ejection fraction (HFrEF) is unclear. Hence, this study investigated the prognostic value of 
left atrial (LA) functional measures such as the left atrial emptying fraction (LAEF) and the 
minimal LA volume in comparison to left atrial volume index (LAVI) in HFrEF patients. 
 
Methods and results: A total of 818 HFrEF patients with left ventricular ejection fractions <45% 
underwent echocardiography. LA volumes were determined by the area-length method from the 
apical 2 chamber and apical 4 chamber view. LAEF, MinLAVI (minimal LA volume indexed to 
body surface area) and LAVI was calculated. End-point was all-cause mortality. During a median 
follow-up of 3.3 years (IQR: 1.8-4.6 years), 121 patients died (14.8%). Follow-up was 100%. In a 
final multivariable model adjusting for clinical and echocardiographic parameters, LAEF, but not 
MinLAVI or LAVI, was an independent predictors of all-cause mortality in HFrEF patients (LAEF: 
HR 1.11, p=0.033, per 5% decrease)(MinLAVI: HR 1.03, p=0.57, per 5mL/m
2
 increase)(LAVI: HR 
1.06, p=0.16, per 5 mL/m
2
 increase).  
 
Conclusion: LAEF is an independent predictor of all-cause mortality in HFrEF patients after 
multivariable adjustment. LAEF provides incremental prognostic value over LAVI in risk 
stratification of HFrEF patients. 
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INTRODUCTION 
Heart failure (HF) represents a large societal burden of disease and has recently been characterized 
as an emerging epidemic[1]. HF is associated with significant mortality, morbidity and healthcare 
expenditures[1]. Echocardiography is an essential tool in the diagnosis, management and risk 
stratification of HF patients[2]. Echocardiographic assessment of HFrEF patients may improve 
survival and overall prognosis due to better and more intensified medical treatment [3].  
 
Left atrial (LA) size and the LA volume index (LAVI) measured by echocardiography are 
established predictors of mortality in HF[4], [5]. Accordingly, measurement of LAVI is included in 
contemporary echocardiographic guidelines[6]. However, the prognostic value of left atrial (LA) 
functional parameters in HFrEF patients has not been a major area of interest thus far[7]. In a study 
of 982 patients admitted with suspicion of HF, LA emptying fraction (LAEF) measured by cardiac 
magnetic resonance imaging (CMRI), but not left ventricular ejection fraction (LVEF), was an 
independent predictor of death, and the prognostic value of LAEF in this population was superior to 
maximal LA volume[8]. These findings suggest that atrial functional measures, such as LAEF and 
the minimal LA volume calculated from the measurements of both maximal and minimal LA 
volume, may contribute with incremental prognostic value in HFrEF. However, little is known 
about the prognostic value of LA functional parameters measured by two-dimensional 
echocardiography in HFrEF. 
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This study therefore aimed to investigate whether left atrial functional measures, such as LAEF and 
the minimal LA volume, hold incremental prognostic value over LAVI and other established 
prognosticators in predicting all-cause mortality in HFrEF patients. 
METHODS 
Data 
Routine echocardiographic examinations are conducted at the Department of Cardiology, Herlev-
Gentofte University Hospital according to a standardised protocol[9].  Results have been stored on a 
local hard drive since 2005.  
 
Study sample  
For this retrospective study, we identified 1102 nonacute consecutive HFrEF patients with a LVEF 
< 45% who were referred to the HF clinic of a large University Hospital in Copenhagen in the 
period 2005-2013. The HFrEF population in the present study has previously been described in 
detail[9]. All patients had been diagnosed with HFrEF by a senior clinician according to 
contemporary guidelines[10], and all patients had a history of angiography to determine coronary 
artery status. We searched the Hospital Database for echocardiograms pertaining to each patient. 
We considered echocardiograms performed at a maximum of 1 year from first admittance to the HF 
clinic (median 30 days before admittance, interquartile range 6 to 56 days before admittance). A 
total of 22 patients did not have an examination within this window and were therefore excluded. 
Furthermore, 15 patients were excluded due to inadequate exam quality. This resulted in 1065 
patients with echocardiograms of sufficient quality within the specified time frame. Then 247 
patients were excluded due to insufficient image quality for the measurement of LA functional 
parameters. This resulted in final study sample of 818 HFrEF patients. Baseline clinical 
characteristics and medications were retrieved from the HF clinic database and were recorded upon 
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first visit to the clinic. Mortality status was retrieved from the Danish National Registry of 
Mortality at follow-up, and follow-up was 100%. 
 
Clinical characteristics 
Diabetes mellitus (DM) was defined as either fasting plasma glucose levels over 7 mmol/L, non-
fasting glucose above 11.1 mmol/L or the use of glucose-lowering medications. Ischemic 
cardiomyopathy (ICMP) was defined either as a history of myocardial infarction, previous 
percutaneous transluminal coronary angioplasty or coronary artery bypass graft surgery (CABG). 
Hypertension was defined as a systolic blood pressure   140mmHg or a diastolic blood pressure   
90 mmHg.  
 
Echocardiography 
Vivid 7 or 9 ultrasound machines (GE Healthcare, Horten, Norway) were used by experienced 
sonographers in all echocardiographic examinations. Echocardiograms were stored in a GE 
Healthcare Image Vault and underwent offline analysis by a single investigator blinded to all 
patient data and outcomes, using Echopac version 12 (GE Healthcare, Horten, Norway).  
 
Conventional echocardiography 
The acquisition of conventional echocardiographic parameters has previously been described in 
detail[9]. We measured the maximum LA volume using the biplane area length method[6] from the 
apical 4 chamber and apical 2 chamber view in end-systole using the frame just prior to mitral valve 
opening. We measured the minimal LA volume using the biplane area length method from the 
apical 4 chamber and apical 2 chamber view in end-diastole using the frame just prior to mitral 
valve closure. LAEF was calculated as LAEF = (maximal LA volume – minimal LA volume)/ 
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maximal LA volume. MinLAVI was calculated as minimal LA volume indexed to body surface 
area (BSA) and LAVI as maximal LA volume indexed to BSA. Our lab has previously 
demonstrated good inter- and intraobserver variability in the measurement of LAEF, minimal LA 
volume and maximal LA volume[11]. In this analysis, the intraobserver coefficients of variation 
(CV) were as follows: LAEF CV = 9.0%; minimal LA volume CV = 10.7%; maximal LA volume 
CV = 10.7%. The interobserver CVs were as follows: LAEF CV = 19.9%; minimal LA volume CV 
= 29.3%; maximal LA volume CV = 24.6%.Tricuspid annular plane systolic excursion (TAPSE) 
was measured using M-mode in the apical 4 chamber view. Pulsed-wave Doppler echocardiography 
in the 4-chamber view was used to assess mitral valve inflow patterns and thus E, A, deceleration 
time (DT) and E/A ratio. In patients with atrial fibrillation, the left atrium does not contract in end-
diastole, and thus no measureable A wave is present[12]. Therefore, we did not determine A or E/A 
in patients with atrial fibrillation. LVEF was obtained using the modified Simpson’s rule[6]. LV 
end-diastolic dimensions were measured from the parasternal long axis view at the level of the 
mitral valve leaflets. These dimensions include the interventricular septum thickness, the LV 
internal diastolic diameter (LVIDd) and the LV posterior wall thickness. These measurements were 
used to calculate the  LV mass by the Devereux formula and LV mass index (LVMI) by division 
with BSA[6]. The early diastolic peak tissue velocity (e’) was determined by placing the range gate 
in each side of the mitral annular plane in a pulsed-wave tissue Doppler recording of the apical 4-
chamber view with subsequent averaging of values to obtain e’. The degree of mitral valve 
regurgitation was graded according to contemporary guidelines using mitral valve morphology and 
Color Doppler imaging[13].  
 
Speckle tracking echocardiography 
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Collection and calculation of strain parameters derived from speckle tracking echocardiography 
have been described in detail elsewhere[9]. Briefly, longitudinal speckle tracking was performed in 
the 3 apical views. A region of interest was defined and created by a semi-automated process, in 
which the operator placed 3 pointers at the endocardial-blood border, 2 in each side of the mitral 
annular plane and one at the apex of the LV, with the program subsequently detecting the 
endocardial border and the myocardial wall thickness. Global longitudinal strain (GLS) was 
calculated from a total of 18 heart wall segments obtained from the apical 4 chamber, apical 2 
chamber and apical long axis views. Hence, 6 segments were averaged from each view to produce a 
single measure from each view. Then, values from each of the three apical views were averaged 
into a single GLS measure.  
 
Ethics 
This study was approved by a regional scientific ethics committee and by the Danish Data 
Protection Agency. The study complies with the second declaration of Helsinki. Informed consent 
is not needed for studies involving the use of hospital record and registry data in Denmark as long 
as the study has been approved by the Danish Data protection Agency and a regional ethics 
committee.  
 
Statistics 
All statistical analyses were carried out using STATA 13 for Mac OS. Statistical significance was 
defined as p<0.05. Continuous variables exhibiting Gaussian distribution were compared using 
Student’s 2-tailed t-test. In table 1, untransformed continuous variables not exhibiting Gaussian 
distribution were reported as median with interquartile ranges (IQR) and were compared using the 
Mann-Whitney U test. Proportions were compared through use of the chi-square test. Linear 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 8 
regression of means was used to analyze trend over tertiles of LAEF. In case of non-Gaussian 
distribution, the Cuzick test for non-parametric trend was used to asses trend over tertiles of 
LAEF[14].  Survival curves were constructed using the Kaplan-Meier method. Poisson cubic spline 
regression was used to estimate mortality rates as a function of LAEF and MinLAVI. To determine 
the number of knots in these spline regression models, we calculated the Akaike Information 
criterion (AIC) for each model and selected the number of knots that yielded the lowest AIC value. 
Cox proportional hazards regression models were utilized to assess the prognostic value of LA 
functional parameters. To determine whether LA functional parameters contributed with 
independent prognostic value, we constructed multivariable models adjusted for known clinical and 
echocardiographic predictors of outcome in HFrEF.  
 
In Model 1 we chose to adjust for important clinical variables (age, sex, mean arterial pressure, 
treatment with diuretics, diabetes and atrial fibrillation). Then, we evaluated the prognostic value of 
all echocardiographic variables available in our study when adjusted for the covariates specified in 
Model 1. The results of these analyses can be found in the Supplemental Material, Supplemental 
Table S1. The purpose of assessing the prognostic value of all available echocardiographic markers 
in Model 1 was to determine which variables proved to be important in this model such that they 
could be selected for entry into Model 2 using a forward-selection approach. Using an entry 
criterion of p 0.15, we chose all echocardiographic variables which fulfilled this significance 
criteria in Model 1 and added these to the adjusting covariates from Model 1 to obtain the covariate 
adjustment for Model 2. Additionally, we also adjusted Model 2 for mitral valve regurgitation 
severity, since this is a known prognosticator in HFrEF. Then, we assessed the prognostic value of 
LAEF, MinLAVI and LAVI when entered individually into Model 2. Then, using an entry criterion 
of p 0.15, we created a Model 3, which besides all the adjusting covariates from Model 2 
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additionally included LAEF, minLAVI and LAVI in the same model (unless they in Model 2 
displayed a p-value > 0.15, in which case they were considered to have “dropped out” per the 
forward selection criteria). Thus, in Models 1 and 2, LAEF, minLAVI and LAVI were tested 
individually. However, in Model 3, to determine which LA parameter was the strongest predictor of 
outcome, LAEF and minLAVI were entered simultaneously into the same model (LAVI was not 
included in this model since it was not significant in Model 2). Harrell’s C-statistics were calculated 
for each predictor to quantify prognostic strength. In this study we included HFrEF patients with a 
LVEF<45%. However, in the newest heart failure guidelines, HFrEF is defined using a 
LVEF<40%[2]. Therefore, we conducted a sensitivity analysis restricting our final multivariable 
model to consider only patients with a LVEF<40% to determine whether this would alter our 
results. Finally, since atrial fibrillation is very prevalent in HFrEF (In this study 15% had atrial 
fibrillation) we conducted a sensitivity analysis to determine whether atrial fibrillation modified the 
prognostic value of the LA functional measures (LAEF and MinLAVI). We conducted stratified 
analysis to analyze the association between LAEF and MinLAVI and outcome in patients with 
atrial fibrillation and in patients without atrial fibrillation. In these subgroup analysis the extent of 
our multivariable adjustment was limited by the number of events in each subgroup (28 events 
occurred in patients with atrial fibrillation, 93 events occurred in patients without atrial fibrillation). 
Hence, when considering only patients with atrial fibrillation we adjusted for age, sex and mean 
arterial pressure. When considering only patients without atrial fibrillation we adjusted for age, sex, 
mean arterial pressure, body mass index, heart rate, ischemic cardiomyopathy, coronary artery 
bypass graft, diabetes and left ventricular ejection fraction, since the higher number of events in this 
subgroup allowed for more extensive adjustment without the risk of overfitting the model. Also, in 
patients with atrial fibrillation, to assess whether the prognostic value of LA functional parameters 
was secondary to LV filling pressure, we assessed the prognostic value of LA functional parameters 
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adjusting only for E, since E correlates well with LV filling pressure in patients with heart 
failure[15]. 
 
RESULTS 
Outcome and follow-up 
Median follow-up time was 3.3 years (IQR: 1.8-4.6 years), and follow-up was 100%. A total of 121 
patients (14.8%) reached the end-point of all-cause mortality.  
 
Baseline characteristics of the population stratified according to tertiles of LAEF 
Decreasing LAEF was significantly associated with increasing age, decreasing systolic BP and 
increasing HR (Table 1). Increasing prevalence of previous pacemaker implantation, previous 
intracardiac defibrillator implantation, previous acute myocardial infarction (AMI) and previous 
episodes of angina pectoris were all significantly associated with decreasing LAEF (Table 1). 
Finally, increasing severity of mitral regurgitation was significantly associated with decreasing 
LAEF (Table 1).  
 
Decreasing LAEF was significantly associated with increasing values of LAVI, MinLAVI, LVIDd, 
LVMI, E-wave, E/A ratio, and E/e’ ratio (Table 1). Decreasing values of LVEF, GLS, TAPSE, A-
wave and DT were all associated with decreasing LAEF (Table 1).  
 
Prediction of all-cause mortality 
LAEF, MinLAVI and LAVI were all significant predictors of outcome in univariable Cox 
regression (Table 2). LAEF and MinLAVI both displayed a significantly higher C-statistics than 
LAVI (p value for difference, p<0.001) (Table 2). Patients in the 1
st
 tertile (worst) of LAEF 
displayed an approximately 4 times greater risk of death from any cause when compared to patients 
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in the 3
rd
 tertile (best) of LAEF (Figure 1). Patients in the 3
rd
 tertile (worst) of MinLAVI displayed 
an approx. 3 times greater risk of death from any cause compared to patients in the 1
st
 tertile (best) 
(Figure 2). Patients in the 3
rd
 tertile (worst) of LAVI displayed an approx. 2.5 times greater risk of 
death from any cause compared to patients in the 1
st
 tertile (best) (Figure 3). In unadjusted analysis, 
we found that the risk of death increased continuously as a function of LAEF, particularly at low 
values of LAEF(Figure 4). The same was true for the unadjusted relationship between MinLAVI 
and the risk of death (Figure 4).  
 
LAEF, MinLAVI and LAVI all remained significant in a multivariable model adjusting for age, 
sex, mean arterial pressure, treatment with diuretics, diabetes and atrial fibrillation (Model 1) (Table 
2). In a multivariable model adjusted for the same parameters as Model 1 with the addition of mitral 
regurgitation, LVEF, GLS, TAPSE, DT, E/e’ and left ventricular end-systolic volume index, LAEF 
and MinLAVI were the only independent echocardiographic predictors of all-cause mortality 
(Model 2) (Table 2). Finally, in a final multivariable model, to determine which variable was the 
strongest predictor of outcome, we added both LAEF and MinLAVI to Model 2, obtaining Model 3: 
In this analysis, only LAEF remained a significant predictor of outcome (LAEF: HR 1.11, 95CI 
1.01-1.23, per 5% decrease, p=0.033) (MinLAVI: HR 1.03, 95CI 0.93-1.15, per 5mL/m
2
 increase, 
p=0.57) (Model 3) (Table 2). Also, since a LVEF<40% is used to diagnose HFrEF in the latest 
guidelines, we analyzed whether restricting our final multivariable model to consider only patients 
with LVEF<40% altered our results. We found that this did not significantly alter our results 
(LAEF: HR 1.10, 95CI 1.02-1.17, p=0.041, per 5% decrease) (MinLAVI: HR 1.02, 95CI 0.91-1.14, 
p=0.59, per 5 mL/m
2
 increase). 
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We also assessed whether atrial fibrillation modified the prognostic value of LAEF and MinLAVI. 
There was no statistically significant interaction between atrial fibrillation and LAEF or MinLAVI 
(LAEF: p for interaction p=0.41)(MinLAVI: p for interaction p=0.051). In a model considering 
only patients with atrial fibrillation adjusting for age, sex and MAP, LAEF and MinLAVI both 
remained independent predictors of outcome (LAEF: HR 1.31, 95CI 1.07-1.60, p=0.008, per 5% 
decrease)(MinLAVI: HR 1.10, 95CI 1.02-1.19, p=0.019, per 5 mL/m
2
 increase). In a model 
adjusting only for E, only LAEF, not MinLAVI or LAVI, remained an independent predictor of 
outcome (LAEF: HR 1.27, 95CI 1.03-.55, per 5% decrease, p=0.023) (MinLAVI: HR 1.09, 95CI 
0.97-1.24, per 5 mL/m
2
, p=0.15) (LAVI: HR 1.06, 95CI 0.94-1.20, per 5 mL/m
2
 increase, p=0.35). 
In a model considering only patients without atrial fibrillation adjusting for age, sex, MAP, BMI, 
HR, ICMP, CABG, DM and LVEF, LAEF and MinLAVI remained independent predictors of 
outcome (LAEF: HR 1.09, 95% CI 1.01-1.17, p=0.032, per 5% decrease)(MinLAVI: HR 1.11, 95% 
CI 1.03-1.20, p=0.009, per 5 mL/m
2
 increase).  
 
 
DISCUSSION  
In this study, we found that both LAVI, minLAVI and LAEF were significant predictors of all-
cause mortality in HFrEF patients, however, after adjusting for clinical and echocardiographic 
parameters, LAEF emerged as the strongest predictor of outcome.  
 
Prognostic value of atrial volumes and function 
Several studies have demonstrated increased LA size to be a consistent predictor of outcome in 
HF[4], [16]. Thus, it is well documented that the maximal LA volume conveys significant 
prognostic information in HFrEF, and assessment of maximal LA volume is included in current 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 13 
guidelines[6]. In our study, we also found LAVI to be a significant univariable predictor of all-
cause mortality in HFrEF. The prognostic value of the maximal LA volume relies on the 
assumption that LA size is a marker of chronically elevated LV filling pressure[17]. A restrictive 
LV filling pattern, determined by Doppler echocardiography, has previously been shown to predict 
all-cause mortality in HFrEF[18]. However, since mitral filling patterns are very dependent on 
loading conditions during examination and can vary widely, especially with volume depletion, the 
LA size may represent a more consistent marker of LV filling pressures[19]. The LA responds to 
increased LV filling pressures with dilation and fibrotic accumulation[19], and, in accordance, 
significant enlargement of the LA is often found in HFrEF[20]. Thus, LA volume is both an 
established and biologically plausible marker of the severity of HF. Recently though, in a study of 
664 HF patients, LAEF measured by CMRI was a superior predictor of survival compared to 
LVEF[8]. Furthermore, in a study of 982 patients admitted with suspicion of HF, LAEF measured 
by cardiac magnetic resonance imaging CMRI, but not LVEF, was an independent predictor of 
death, and the prognostic value of LAEF in this population was superior to maximal LA volume[8]. 
This indicates that LA functional measures may offer more prognostic value than LAVI. This is 
supported by the results of our study, since we found LAEF to offer incremental prognostic value 
over to LAVI in HFrEF.  
 
Why LA function may offer more prognostic value than LAVI has not been fully elucidated. One 
explanation may be that LAEF is a stronger correlate of LV filling pressure than the maximal LA 
volume. The LA is directly exposed to the LV filling pressure in end diastole during the LA 
contraction. Therefore, the minimal LA volume, which is included in the calculation of LAEF, is a 
balance between atrial afterload (LV filling pressure) and atrial contractile function. In a CMRI 
study of patients undergoing clinically indicated left heart catheterization, LAEF and the LA 
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minimal volume were superior to the maximal LA volume in identifying increased LV filling 
pressure[21]. Furthermore, the minimal LA volume measured by 3-dimensional echocardiography 
has been shown to display a stronger association to diastolic function than the maximal LA 
volume[22]. The minimal LA volume has also been shown to be more strongly correlated to 
Natriuretic peptide levels in a community based sample when compared to LAVI[23]. Hence, these 
considerations along with our results suggest that LAEF be a better marker of LV filling pressure 
and congestion than LAVI, and as a result, may offer prognostic value over LAVI in predicting 
outcome in HFrEF.  
 
It is also possible that part of the prognostic value of LA functional measures found in this study is 
due to an ability to quantify primary myocardial disease independent of the relation to LV filling 
pressure. In a study of ischemic cardiomyopathy and idiopathic dilated cardiomyopathy patients, 
authors found that patients with idiopathic dilated cardiomyopathy had significantly lower LAEF 
even though they had similar systolic and diastolic function[24]. Likewise, in a study comparing 
patients with dilated cardiomyopathy to patients with aortic stenosis, atrial systolic function as 
determined by atrial active emptying fraction was significantly lower in patients with dilated 
cardiomyopathy even though there was no difference in maximal LA volume or in 
hemodynamically assessed LV filling pressure[25]. This difference in LA function cannot be 
explained by differences in LA maximal volume or LV filling pressure. In our study, we corrected 
our multivariable model for E/e’, a marker of LV filling pressure, yet LAEF remained a strong 
predictor of outcome. Hence, it is possible that at least part of the prognostic value conveyed by 
LAEF in HFrEF may stem from an ability to quantify generalized myocardial disease.  
 
LAEF and MinLAVI 
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As discussed, it is likely that some of the prognostic value of LAEF is due to the strong correlation 
to LV filling pressure[21]. However, an interesting finding was the lack of prognostic value of 
MinLAVI when both LAEF and MinLAVI were entered into the final multivariable model. This 
suggests that the prognostic value of LAEF is not only carried by the minimal LA volume and its 
relation to LV filling pressure. LAEF is not only determined by LA contractile function, but also by 
LA reservoir and conduit functions[26], [27]. The LA has 3 important functions throughout the 
cardiac cycle, and all contribute to optimal cardiac performance[26]–[30]: 1) during the reservoir 
phase in systole, the left atrium acts as a reservoir for pulmonary venous return while the mitral 
valve is closed, 2) during the conduit phase in early diastole, the left atrium acts as a conduit for 
blood entering the left ventricle, and 3) during end-diastole, the left atrium acts as a booster pump 
augmenting left ventricular filling right before ventricular systole. Aging is associated with reduced 
LA compliance, reduced LA reservoir function and reduced conduit function, partly due to 
accumulation of LA fibrosis and increased LA stiffness[31]–[33]. This reduction in reservoir and 
conduit function associated with normal aging is compensated for by an increase in LA booster 
pump function[26], [30], [33]. Similarly, in early heart failure, increased LA pump function 
compensates for impaired LV function[26], [30], [33], [34]. However, as LV function deteriorates 
further with progression heart failure, the workload imposed on the LA exceeds its reserve capacity 
and LA pump failure ensues[35], [36]. To maintain LV filling and stroke volume, the reservoir and 
conduit functions must compensate for decreased LA pump function[26], [30], [35], [36]. Thus, 
since LAEF represents all three functions of the LA, LAEF may be able to identify patients with 
advanced disease in whom LA reservoir and conduit function cannot compensate for LA failure. 
This notion is supported by our finding that LAEF, but not MinLAVI, also predicted mortality in 
patients with atrial fibrillation: In atrial fibrillation, LA contractile function is absent and thus LAEF 
does not represent LA systolic function and booster pump function in atrial fibrillation rhythm. LA 
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compliance is reduced and LA stiffness is increased in patients with atrial fibrillation due to LA 
fibrosis and impaired LA relaxation (due to constant fibrillation)[37], and since especially LA 
reservoir function is determined by LA compliance, this may result in impaired reservoir 
function[26], [27], [30]. Hence, the prognostic value of LAEF in patients with atrial fibrillation may 
stem from an ability to quantify reservoir and conduit function, allowing the identification of 
patients with poor LA compliance and high LA stiffness, who cannot compensate for the loss of 
contractile function. Alternatively, invasive hemodynamic studies have demonstrated that the 
irregular ventricular rate and the loss of atrial filling caused by AF  significantly increase 
pulmonary capillary wedge pressure and contribute to diastolic dysfunction[8]. In HF patients with 
AF, pronounced diastolic dysfunction could potentially antagonize LA emptying during diastole 
and lead to reduced LAEF. Thus, this may also explain part of why LAEF was a strong predictor of 
mortality in patients with atrial fibrillation in our study. However, these considerations should be 
confirmed in future experimental studies.  
 
Limitations 
Some limitations to this study must be acknowledged. None of the patients were suspected of 
restricted cardiac amyloidosis. However, as is the case for all other HFrEF studies, and for HFpEF 
studies, the presence of cardiac amyloidosis as a cause of HF symptoms can never be excluded 
completely. Furthermore, we did not have information on whether some patients may have 
developed HFrEF in due to specific genetic mutations, rare conditions or viral infections.  These 
considerations are important since myocarditis, amyloidosis and other infiltrative diseases may 
cause atrial myopathy and affect LA function independently of other disease mechanisms. Also, we 
did not have information on important clinical variables such as natriuretic peptide levels or New 
York Heart Association functional class. Since these variables contribute with valuable prognostic 
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information in HFrEF[38], [39], this is another limitation. In this study we did not have access to 
information regarding the specific cause of death, and as a result we could not analyze the 
association between LA functional parameters and cardiovascular mortality. However, when 
considering that approximately 80% of HFrEF patients die from cardiovascular causes[40], we feel 
that our results remain valid even though our outcome was all-cause mortality. Furthermore, we did 
not have information on heart failure hospitalizations during follow-up. Since heart failure 
hospitalization is associated with significant healthcare costs[41], this would have been useful. 
Multiple statistical tests were performed in this study but no adjustment for multiple comparisons 
was made. Due to a high degree of multicollinearity between LAEF and MinLAVI, these variables 
were tested separately in the multivariable models. Therefore, it was difficult to assess whether one 
was superior to the other. However, since LAEF and MinLAVI remained independent predictors of 
outcome when tested separately in the final multivariable model but LAVI did not, we may still 
conclude that LAEF and MinLAVI are superior to L VI in predicting outcome in HFrEF. Lastly, 
the study population was mainly of Caucasian ethnicity, and therefore our results cannot be applied 
to other ethnicities.   
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CONCLUSION 
LAEF is an independent predictor of all-cause mortality in HFrEF patients after multivariable 
adjustment. LAEF provides incremental prognostic value over LAVI in risk stratification of HFrEF 
patients. 
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FIGURE LEGENDS 
 
Figure 1: Mortality of the population stratified according to tertiles of left atrial emptying fraction 
(LAEF). The tertile cut-offs are 1. tertile, LAEF < 28%; 2. tertile, LAEF = 28-43 %; 3. tertiler. 
LAEF > 43%.  
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Figure 2: Mortality of the population stratified according to tertiles of end diastolic (minimal)  left 
atrial volume indexed to body surface area (MinLAVI) .The tertile cut-offs are 1. tertile, MinLAVI < 
14 mL/m
2
; 2. tertile, MinLAVI = 14-23 mL/m
2
; 3. tertile MinLAVI > 23 mL/m
2
. 
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Figure 3: Mortality of the population stratified according to tertiles of left atrial volume index 
(LAVI). The tertile cut-offs are 1. tertile, LAVI < 24 mL/m
2
; 2. tertile, LAVI = 24-34 mL/m
2
; 3. 
tertile, LAVI > 34 mL/m
2
. 
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Figure 4: The association between all-cause mortality and measures of left atrial function. The 
curves display the unadjusted mortality rate with 95% confidence intervals as a function of the left 
atrial emptying fraction and the minimal left atrial volume index. A Poisson regression model was 
used to estimate incidence rates. 
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TABLE 1 
Patients stratified according to tertiles of LAEF. 
      
Demographics All Patients  1. Tertile (LAEF < 28%) 2. Tertile (LAEF = 28-43%) 3. Tertile (LAEF > 43%) P for trend 
N  818 273 273 272  
Age (years) 66.4 (11.4) 68.6 (9.9) 66.0 (11.6) 64.5 (12.2) <0.001 
Male  600 (73.4%) 205 (75.1%) 198 (72.5%) 197 (72.4%) 0.48 
Clinical Characteristics      
Systolic BP (mmHG) 129.9 (20.7) 126.9 (20.3) 131.3 (21.3) 131.6 (20.3) 0.008 
Diastolic BP (mmHG) 74.7 (12.4) 74.5 (12.2) 74.9 (12.3) 74.6 (12.7) 0.96 
Pulse Pressure (mmHG) 55.2 (16.8) 52.4 (16.1) 56.4 (17.7) 57.0 (16.3) 0.051 
MAP (mmHG) 93.1 (13.5) 92.0 (13.4) 93.7 (13.5) 93.6 (13.6) 0.17 
Hypertension 337 (41.2%) 107 (39.2%) 113 (41.4%) 117 (43.0%) 0.66 
BMI (kg/m
2
) 26.4 (4.8) 26.2 (4.1) 26.4 (4.8) 26.5 (5.3) 0.44 
Diabetes Mellitus  93 (11.4%) 33 (12.1%) 29 (10.6%) 31 (11.4%) 0.80 
Heart rate (BPM) 74 (16) 78 (17) 73 (15) 70 (13) <0.001 
Ischemic Cardiomyopathy 457 (55.9%) 135 (49.5%) 161 (59.0%) 161 (59.2%) 0.02 
History of AMI   384 (46.9%) 111 (40.7%) 133 (48.7%) 140 (51.5%) 0.011 
CABG 159 (19.4%) 56 (20.5%) 60 (22.0%) 43 (15.8%) 0.17 
RAS Blockade  647 (79.1%) 218 (79.9%) 222 (81.3%)   207 (76.1%) 0.28 
Beta Blocker  542 (66.3%) 183 (67.0%) 183 (67.0%) 176 (64.7%) 0.57 
Spironolactone 122 (14.9%) 44 (16.1%) 33 (12.1%) 45 (16.5%) 0.89 
Diuretics  412 (50.4%) 141 (51.6%) 141 (51.6%) 130 (47.8%)   0.37 
Antiarrhythmics  37 (4.5%) 12 (4.4%) 12 (4.4%) 13 (4.8%) 0.83 
Total Cholesterol (mmol/L)  4.46 (1.14)  4.44 (1.21) 4.43 (1.07) 4.51 (1.15) 0.49 
Atrial Fibrillation 125 (15.3%) 93 (34.1%) 25 (9.2%) 7 (2.6%) <0.001 
Permanent Atrial Fibrillation 113 (13.8%) 87 (31.9%) 22 (8.1%) 4 (1.5%) <0.001 
Paroxysmal Atrial Fibrillation 12 (1.5%) 6 (2.2%) 3 (1.1%) 3 (1.1%) 0.47 
Mitral Regurtitation     0.002 
  None 305 (37.3% 87 (31.9%) 109 (39.9%) 109 (40.1%)  
  Mild 439 (53.7%) 148 (54.2%) 140 (51.3%) 151 (55.5%)  
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  Moderate 68 (8.3) 35 (12.8%) 21 (7.7%) 12 (4.4%)  
  Severe 6 (0.7%) 3 (1.1%) 3 (1.1%) 0 (0.0%)    
Echocardiography      
MinLAVI (ml/m
2
) 21.1 (13.3) 32.6 (15.3) 18.8 (7.0) 11.9 (5.1) <0.001 
LAVI (ml/m
2
) 30.9 (13.8) 39.0 (16.7) 28.9 (10.1) 25.0 (9.4) <0.001 
LVEF (%) 27.8 (9.1) 23.9 (9.0) 28.7 (8.6) 30.7 (8.4) <0.001 
GLS (%) 9.7 (3.3) 8.0 (2.8) 10.0 (3.2) 11.1 (3.3) <0.001 
TAPSE (cm) 1.9 (0.6) 1.6 (0.5) 1.9 (0.6) 2.1 (0.5) <0.001 
LVIDd (cm)  5.6 (1.0) 5.9 (1.0) 5.6 (1.0) 5.5 (0.9) <0.001 
LVMI (g/m
2
)  120.9 (38.9) 128.4 (36.4) 120.2 (37.6) 114.1 (41.5) <0.001 
E (m/s) 0.81 (0.2) 0.94 (0.31) 0.81 (0.27) 0.71 (0.23) <0.001 
A* (m/s) 0.71 (0.26) 0.56 (0.28) 0.72 (0.28) 0.77 (0.23) <0.001 
E/A*  1.02 (0.74-1.65) 1.93 (1.09-2.93) 1.03 (0.79-1.60) 0.84 (0.67-1.18) <0.001 
DT (ms) 189 (79) 168 (74) 190 (72) 210 (81) <0.001 
e’ (cm/s) 6.9 (2.5) 7.1 (2.7) 6.8 (2.3) 6.7 (2.5) 0.15 
E/e’  11.8 (8.9-15.9) 12.9 (9.5-17.6) 11.3 (9.0-15.7) 10.5 (7.9-14.3) <0.001 
 
*Measured only in patients without atrial fibrillation, since no A wave is present in atrial fibrillation rhythm 
BP, blood pressure; MAP, mean arterial pressure; BMI, body mass index; BPM, beats per minute; AMI, acute myocardial infarction; CABG, coronary artery bypass graft 
surgery; RAS, renin-angiotensin system; LAEF, left atrial emptying fraction; LAi, left atrial expansion index; MinLAVI, minimal left atrial volume indexed to body surface 
area; LAVI, left atrial volume index; LVEF, left ventricular ejection fraction; GLS, global longitudinal strain; TAPSE, tricuspid annular plane systolic excursion; LVIDd, left 
ventricular inner diameter at end diastole; LVMI, left ventricular mass index; DT, deceleration time. 
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TABLE 2 
Prediction of all-cause mortality using Cox regressions. 
    
Unadjusted (818 patients; 121 events) Hazard Ratio  P-value  
LAEF (per 5% decrease) HR 1.21, 95CI 1.14-1.29, C-stat: 0.675 <0.001 
MinLAVI (per 5ml/m
2
 increase) HR 1.16, 95CI 1.12-1.21, C-stat: 0.661 <0.001 
LAVI (per 5 ml/m
2
 increase) HR 1.14, 95CI 1.09-1.19, C-stat: 0.620 <0.001 
Model 1 (817 patients; 121 events) Hazard Ratio P-value 
LAEF (per 5% decrease) HR 1.17, 95CI 1.1.10-1.25 <0.001 
MinLAVI (per 5ml/m
2
 increase) HR 1.13, 95CI 1.07-1.18 <0.001 
LAVI (per 5 ml/m
2
 increase) HR 1.10, 95CI 1.05-1.16 <0.001 
Model 2 (727 patients; 106 events) Hazard Ratio P-value 
LAEF (per 5% decrease) HR 1.13, 95CI 1.05-1.23 0.002 
MinLAVI (per 5ml/m
2
 increase) HR 1.11, 95CI 1.02-1.21 0.0018 
LAVI (per 5 ml/m
2
 increase) HR 1.06, 95CI 0.98-1.16 0.16 
Model 3 (727 patients; 106 events) Hazard Ratio P-value 
LAEF (per 5% decrease) HR 1.11, 95CI 1.01-1.23 0.033 
MinLAVI (per 5ml/m
2
 increase) HR 1.03, 95CI 0.93-1.15 0.57 
   
   
 
Model 1 is adjusted for age, sex, diabetes, mean arterial pressure, treatment with diuretics and atrial fibrillation.  
Model 2 is adjusted for the same variables as model 1 with the addition of mitral regurtitation, LVEF, GLS, TAPSE, DT, E/e’ and LVESV index. LAEF, left atrial emptying 
fraction; MinLAVI, minimal left atrial volume index; LAVI, left atrial volume index, LVEF, left ventricular ejection fraction; GLS, global longitudinal strain; TAPSE, 
tricuspid annular plane systolic excursion; LVIDd, left ventricular inner diameter at end-diastole; LVMI, left ventricular mass index; DT, deceleration time of the E-wave; 
LVESV, left ventricular end-systolic volume. 
Model 3 is identical to Model 2 with the addition that LAEF and MinLAVI were entered simultaneously into the same model.  
 
